secwatch.observer — SEC 8-K summary
======================================

Issuer:     CURIS INC (CRIS)
CIK:        0001108205
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0001193125-22-212487
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Curis Q2 net loss widens to $15.9M; appoints new CFO; emavusertib combo shows tumor reduction in 8 of 9
--------------------------------------------------------------------------------

- Net loss of $15.9M ($0.17/sh) vs $10.8M ($0.12) in Q2 2021; revenue flat at $2.4M.
- Cash and investments $107.2M as of June 30, 2022; cash runway expected into 2024.
- Emavusertib + ibrutinib combo: tumor reduction in 8 of 9 evaluable patients; 2 CR, 2 PR; potential to overcome ibrutinib resistance.
- Appointed Diantha Duvall as CFO effective Aug 5, 2022, succeeding Bill Steinkrauss (resigning).
- Working with FDA to resolve partial clinical holds on emavusertib enrollment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1108205/000119312522212487/0001193125-22-212487-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1108205/000119312522212487/d249846d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-212487

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer